ENVB Share Price Performance
US$1.15
-7.39 (-86.54%)
Price US$1.15
Share PriceUS$1.15
ENVB Community Narratives
There are no narratives available yet.
Recent ENVB News & Updates
No updates
Enveric Biosciences, Inc. Key Details
Last Reported Earnings
Mar 31, 2025
Next Reporting Earnings
n/a
- Earnings per share (EPS)
- -3.76
- Gross Margin
- 0%
- Net Profit Margin
- 0%
- Debt/Equity Ratio
- 0%
Enveric Biosciences, Inc. Competitors
About ENVB
- Founded
- n/a
- Employees
- 6
- CEO
- WebsiteView website
Enveric Biosciences, Inc., a biotechnology company, engages in the development of small-molecule therapeutics for the treatment of anxiety, depression, and addiction disorders. The company offers product candidates are EB-002, an active metabolite of psilocybin, which is in preclinical development stage for the treatment of anxiety disorders; and EB-003 that is in preclinical development stage for the treatment mental health. It also focuses on the development of cannabinoid conjugate molecules for the treatment of pain and cancer. The company is headquartered in Naples, Florida.
U.S. Market Performance
- 7 Days: -0.2%
- 3 Months: 12.2%
- 1 Year: 22.4%
- Year to Date: 7.7%
The Communication Services sector gained 3.4% while the market remained flat over the last week. As for the longer term, the market has risen 22% in the past 12 months. Looking forward, earnings are forecast to grow by 15% annually. Market details ›
This week, we’re diving deeper into the world of agentic AI. We’re zeroing in on the core technologies that make these intelligent agents actually reliably work. We explore what all this could mean for software, start-ups, and most importantly, the opportunities and risks each industry faces by adopting Agentic AI.
Continue reading